拉丁美洲成人侵袭性肺炎球菌病:血清型分布与疫苗覆盖
该横断面分析基于阿根廷、墨西哥和巴西的SIREVA II监测数据,纳入5012例50岁以上实验室确诊侵袭性肺炎球菌病(IPD)成人病例。结果显示PCV21在50-59岁和≥60岁成人中的预估覆盖率分别为67-72%和55-69%,均高于PCV20及其他较早代次疫苗,PCV21独有血清型约占19-26%的疾病负担。
要点
- PCV21对50-59岁和≥60岁成人IPD的预估覆盖率分别为67-72%和55-69%。
- PCV21独有血清型约占19-26%的IPD,且持续超过PCV20独有血清型。
- 血清型3在三国均占主导,8、19A和12F也有额外贡献。
核心结论
- 在阿根廷、巴西和墨西哥,PCV21对成人IPD的潜在覆盖率显著高于PCV20及更早代次肺炎球菌疫苗。
- 若纳入成人免疫规划并达到足够接种率,PCV21可实质性降低IPD负担。
研究设计与样本
- 横断面分析,基于SIREVA II监测数据:阿根廷和墨西哥为2016-2023年,巴西为2016-2024年。
- 纳入50-59岁和≥60岁、实验室确诊IPD且有血清型数据的成人,共5012例。
主要发现
- ≥60岁成人疾病负担更高,2020-2021年期间明显下降后出现反弹。
- 血清型3在各国均占主导,血清型8、19A和12F也有额外贡献。
- 50-59岁成人中,PCV21覆盖率67-72%,PCV20为59-63%,PPSV23为61-70%,PCV15为41-44%,PCV13为37-42%,PCV10为7-15%。
- ≥60岁成人中,PCV21覆盖率55-69%,PCV20为49-67%,PPSV23为46-61%,PCV15为26-46%,PCV13为1-15%,PCV10为1-11%。
- PCV21独有血清型约占19-26%的疾病,且持续超过PCV20独有血清型。
关键数值与推荐
- 50-59岁成人IPD预估覆盖率:PCV10 7-15%、PCV13 37-42%、PCV15 41-44%、PCV20 59-63%、PPSV23 61-70%、PCV21 67-72%。
- ≥60岁成人IPD预估覆盖率:PCV10 1-11%、PCV13 1-15%、PCV15 26-46%、PCV20 49-67%、PPSV23 46-61%、PCV21 55-69%。
- PCV21独有血清型约占IPD的19-26%,持续超过PCV20独有血清型。
临床怎么用
- 在阿根廷、巴西和墨西哥的成人IPD防控中,PCV21较PCV20及更早代次疫苗可覆盖更高比例的致病血清型。
- 将PCV21纳入成人免疫规划并保障足够接种率,可能实质性降低成人IPD负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive pneumococcal disease (IPD) causes substantial morbidity and mortality among adults in Latin America. Despite high pediatric pneumococcal conjugate vaccine (PCV), uptake, adult coverage remains low, and residual IPD burden persists. Among currently available PCVs, PCV21 and PCV20 are the newest higher-valency formulations. PCV21 includes eight unique serotypes to address residual adult disease. This analysis quantified the proportion of IPD cases in Argentina, Brazil, and Mexico attributable to PCV21 serotypes compared with those in other pneumococcal vaccines to estimate potential disease coverage. METHODS: We conducted a cross-sectional analysis of SIREVA II surveillance data from Argentina and Mexico (2016-2023) and Brazil (2016-2024). Adults aged 50-59 years and ≥ 60 years with laboratory-confirmed IPD and available serotype data were included. We summarized serotype distributions and estimated the proportion of IPD attributable to PCV21 and other recommended vaccines by country, age group, and year. Secondary analyses compared PCV21-unique with PCV20-unique serotypes. RESULTS: A total of 5012 IPD cases were identified, with a higher burden among adults ≥60 years and a marked decline during 2020-2021 followed by a rebound. Serotype 3 predominated across countries, with additional contributions from serotypes 8, 19A, and 12F. Higher-valency vaccines consistently showed greater coverage. In adults aged 50-59 years, coverage ranged from 7-15% for PCV10, 37-42% for PCV13, 41-44% for PCV15, 59-63% for PCV20, 61-70% for PPSV23, and 67-72% for PCV21. In those aged ≥60 years, coverage ranged from 1-11%, 1-15%, 26-46%, 46-61%, 49-67%, and 55-69%, respectively. PCV21-unique serotypes accounted for approximately 19-26% of disease and consistently exceeded PCV20-unique serotypes. CONCLUSIONS: PCV21 offers substantially broader potential coverage for adult IPD than PCV20 and earlier-generation PCVs in Argentina, Brazil, and Mexico. If incorporated into adult immunization programs with sufficient uptake, PCV21 could meaningfully reduce IPD burden.
引用
- Martino A, Urrego-Reyes J, Cervenka J, et al. Invasive pneumococcal disease in Latin America: serotype distribution and vaccine coverage among adults in Mexico, Brazil, and Argentina. Vaccine. 2026. PMID: 42537290. doi:10.1016/j.vaccine.2026.128947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。